Baidu
map

Neurology:复发缓解多发性硬化症患者治疗方案选择——芬戈莫德 vs富马酸二甲酯

2018-06-07 zhangfan MedSci原创

研究发现,芬戈莫德和富马酸二甲酯对复发缓解多发性硬化症患者均有较好的治疗效果,但芬戈莫德对中途换药患者的疗效优于富马酸二甲酯

近日研究人员比较了芬戈莫德(FNG)和富马酸二甲酯(DMF)对复发缓解性多发性硬化症(RRMS)患者无明显疾病活动(NEDA)状态影响。

RRMS患者参与研究,依据首次治疗或治疗方案转换对患者分层,依据同质基线特征建立倾向评分(PS)对参与者进行匹配,主要终点为NEDA-3,即无复发、无残疾恶化、无MRI活动病变特征。

483名患者接受FNG治疗,456人接受DMF治疗,经PS匹配后,各组均有275名患者参与研究。随访18个月后,组间NEDA-3率相近(FNG vs DMF 73% vs 70%; HR=0.74, p = 0.078)。亚组分析显示,二种药物对初次治疗患者有相近的疗效(n =170, HR 1.15, p = 0.689),但FNG对转换治疗方案患者的效果优于DMF(n=380, HR 0.57, p = 0.007)。

研究发现,芬戈莫德和富马酸二甲酯对复发缓解多发性硬化症患者均有较好的治疗效果,但芬戈莫德对中途换药患者的疗效优于富马酸二甲酯。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1889909, encodeId=52241889909c5, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Jul 23 07:05:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905060, encodeId=f65c1905060df, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Fri Dec 07 21:05:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983011, encodeId=722c198301166, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 27 02:05:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000446, encodeId=372e2000446d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Mar 28 05:05:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323314, encodeId=bd53323314b6, content=这真是个不错的好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83eotdaO1641OCcgmIbImUjgibd5RqzVgPV1xroCjVvMMm13U30RA25aXdlKuCxYmTk77sa5b2k8Mn6w/132, createdBy=8c52106446, createdName=高枫, createdTime=Mon Jun 11 14:44:33 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585610, encodeId=33301585610d3, content=<a href='/topic/show?id=befc465e767' target=_blank style='color:#2F92EE;'>#富马酸二甲酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46577, encryptionId=befc465e767, topicName=富马酸二甲酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc6217239506, createdName=d830378, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620953, encodeId=a418162095346, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322259, encodeId=bdea322259dd, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jun 07 14:46:58 CST 2018, time=2018-06-07, status=1, ipAttribution=)]
    2018-07-23 jml2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1889909, encodeId=52241889909c5, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Jul 23 07:05:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905060, encodeId=f65c1905060df, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Fri Dec 07 21:05:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983011, encodeId=722c198301166, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 27 02:05:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000446, encodeId=372e2000446d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Mar 28 05:05:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323314, encodeId=bd53323314b6, content=这真是个不错的好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83eotdaO1641OCcgmIbImUjgibd5RqzVgPV1xroCjVvMMm13U30RA25aXdlKuCxYmTk77sa5b2k8Mn6w/132, createdBy=8c52106446, createdName=高枫, createdTime=Mon Jun 11 14:44:33 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585610, encodeId=33301585610d3, content=<a href='/topic/show?id=befc465e767' target=_blank style='color:#2F92EE;'>#富马酸二甲酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46577, encryptionId=befc465e767, topicName=富马酸二甲酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc6217239506, createdName=d830378, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620953, encodeId=a418162095346, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322259, encodeId=bdea322259dd, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jun 07 14:46:58 CST 2018, time=2018-06-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1889909, encodeId=52241889909c5, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Jul 23 07:05:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905060, encodeId=f65c1905060df, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Fri Dec 07 21:05:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983011, encodeId=722c198301166, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 27 02:05:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000446, encodeId=372e2000446d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Mar 28 05:05:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323314, encodeId=bd53323314b6, content=这真是个不错的好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83eotdaO1641OCcgmIbImUjgibd5RqzVgPV1xroCjVvMMm13U30RA25aXdlKuCxYmTk77sa5b2k8Mn6w/132, createdBy=8c52106446, createdName=高枫, createdTime=Mon Jun 11 14:44:33 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585610, encodeId=33301585610d3, content=<a href='/topic/show?id=befc465e767' target=_blank style='color:#2F92EE;'>#富马酸二甲酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46577, encryptionId=befc465e767, topicName=富马酸二甲酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc6217239506, createdName=d830378, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620953, encodeId=a418162095346, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322259, encodeId=bdea322259dd, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jun 07 14:46:58 CST 2018, time=2018-06-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1889909, encodeId=52241889909c5, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Jul 23 07:05:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905060, encodeId=f65c1905060df, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Fri Dec 07 21:05:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983011, encodeId=722c198301166, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 27 02:05:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000446, encodeId=372e2000446d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Mar 28 05:05:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323314, encodeId=bd53323314b6, content=这真是个不错的好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83eotdaO1641OCcgmIbImUjgibd5RqzVgPV1xroCjVvMMm13U30RA25aXdlKuCxYmTk77sa5b2k8Mn6w/132, createdBy=8c52106446, createdName=高枫, createdTime=Mon Jun 11 14:44:33 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585610, encodeId=33301585610d3, content=<a href='/topic/show?id=befc465e767' target=_blank style='color:#2F92EE;'>#富马酸二甲酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46577, encryptionId=befc465e767, topicName=富马酸二甲酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc6217239506, createdName=d830378, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620953, encodeId=a418162095346, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322259, encodeId=bdea322259dd, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jun 07 14:46:58 CST 2018, time=2018-06-07, status=1, ipAttribution=)]
    2019-03-28 yinhl1978
  5. [GetPortalCommentsPageByObjectIdResponse(id=1889909, encodeId=52241889909c5, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Jul 23 07:05:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905060, encodeId=f65c1905060df, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Fri Dec 07 21:05:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983011, encodeId=722c198301166, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 27 02:05:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000446, encodeId=372e2000446d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Mar 28 05:05:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323314, encodeId=bd53323314b6, content=这真是个不错的好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83eotdaO1641OCcgmIbImUjgibd5RqzVgPV1xroCjVvMMm13U30RA25aXdlKuCxYmTk77sa5b2k8Mn6w/132, createdBy=8c52106446, createdName=高枫, createdTime=Mon Jun 11 14:44:33 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585610, encodeId=33301585610d3, content=<a href='/topic/show?id=befc465e767' target=_blank style='color:#2F92EE;'>#富马酸二甲酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46577, encryptionId=befc465e767, topicName=富马酸二甲酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc6217239506, createdName=d830378, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620953, encodeId=a418162095346, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322259, encodeId=bdea322259dd, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jun 07 14:46:58 CST 2018, time=2018-06-07, status=1, ipAttribution=)]
    2018-06-11 高枫

    这真是个不错的好消息

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1889909, encodeId=52241889909c5, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Jul 23 07:05:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905060, encodeId=f65c1905060df, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Fri Dec 07 21:05:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983011, encodeId=722c198301166, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 27 02:05:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000446, encodeId=372e2000446d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Mar 28 05:05:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323314, encodeId=bd53323314b6, content=这真是个不错的好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83eotdaO1641OCcgmIbImUjgibd5RqzVgPV1xroCjVvMMm13U30RA25aXdlKuCxYmTk77sa5b2k8Mn6w/132, createdBy=8c52106446, createdName=高枫, createdTime=Mon Jun 11 14:44:33 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585610, encodeId=33301585610d3, content=<a href='/topic/show?id=befc465e767' target=_blank style='color:#2F92EE;'>#富马酸二甲酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46577, encryptionId=befc465e767, topicName=富马酸二甲酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc6217239506, createdName=d830378, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620953, encodeId=a418162095346, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322259, encodeId=bdea322259dd, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jun 07 14:46:58 CST 2018, time=2018-06-07, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1889909, encodeId=52241889909c5, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Jul 23 07:05:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905060, encodeId=f65c1905060df, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Fri Dec 07 21:05:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983011, encodeId=722c198301166, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 27 02:05:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000446, encodeId=372e2000446d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Mar 28 05:05:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323314, encodeId=bd53323314b6, content=这真是个不错的好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83eotdaO1641OCcgmIbImUjgibd5RqzVgPV1xroCjVvMMm13U30RA25aXdlKuCxYmTk77sa5b2k8Mn6w/132, createdBy=8c52106446, createdName=高枫, createdTime=Mon Jun 11 14:44:33 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585610, encodeId=33301585610d3, content=<a href='/topic/show?id=befc465e767' target=_blank style='color:#2F92EE;'>#富马酸二甲酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46577, encryptionId=befc465e767, topicName=富马酸二甲酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc6217239506, createdName=d830378, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620953, encodeId=a418162095346, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322259, encodeId=bdea322259dd, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jun 07 14:46:58 CST 2018, time=2018-06-07, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1889909, encodeId=52241889909c5, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon Jul 23 07:05:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905060, encodeId=f65c1905060df, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Fri Dec 07 21:05:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983011, encodeId=722c198301166, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 27 02:05:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000446, encodeId=372e2000446d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Mar 28 05:05:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323314, encodeId=bd53323314b6, content=这真是个不错的好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83eotdaO1641OCcgmIbImUjgibd5RqzVgPV1xroCjVvMMm13U30RA25aXdlKuCxYmTk77sa5b2k8Mn6w/132, createdBy=8c52106446, createdName=高枫, createdTime=Mon Jun 11 14:44:33 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585610, encodeId=33301585610d3, content=<a href='/topic/show?id=befc465e767' target=_blank style='color:#2F92EE;'>#富马酸二甲酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46577, encryptionId=befc465e767, topicName=富马酸二甲酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc6217239506, createdName=d830378, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620953, encodeId=a418162095346, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sat Jun 09 05:05:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322259, encodeId=bdea322259dd, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jun 07 14:46:58 CST 2018, time=2018-06-07, status=1, ipAttribution=)]
    2018-06-07 天地飞扬

    了解一下.谢谢分享!

    0

相关资讯

Neurology:芬戈莫德治疗导致的进行性多灶性白质脑病风险极低

研究认为,对于未接受过那他珠单抗治疗的患者,接受芬戈莫德导致的进行性多灶性白质脑病风险极低,每1000患者的发病率为0.069,每100000患者年发病3.12例

Neurology:芬戈莫德治疗多发性硬化可增黄斑体积

  研究表明:MS患者接受芬戈莫德治疗与中等程度、相对快速的黄斑容积增加相关。   芬戈莫德是一种鞘氨醇-1-磷酸受体调节剂,是首个口服治疗多发性硬化的药物,在2010年获FDA批准用于多发性硬化的治疗,商品名Gilenya。为了研究芬戈莫德能否在总体上带来视网膜组织体积的增加,美国加州大学旧金山分校神经科多发性硬化研究中心的Rachel Nolan学士等人员进行了一项研究,研究结果发

Cancer Cell:芬戈莫德或可用于结直肠癌

 弗吉尼亚联邦大学梅西癌症中心的科学家在发现可诱发慢性肠道炎症和促进结直肠癌恶化的相关机制之后,近日又通过研究发现,用于治疗多发性硬化症的药物芬戈莫德或能削弱和消除结肠炎相关癌症(CAC)的发展。   这项发表在《癌细胞》杂志网页版上的研究是由梅西癌症中心的Sarah Spiegel博士领导进行的。Speigel博士的研究团队发现,鞘氨醇激酶1(SphK1)分泌增加会导致肠道内膜细

Nat Neurosci:芬戈莫德或可帮助忘记疼痛

许多人在发生车祸或严重外伤后,会受到“创伤后应激障碍”的困扰。一项最新研究发现,一种治疗多发性硬化症的药物或许可以帮助减轻这种创伤记忆。 这种药物名为芬戈莫德,它含有的一种小分子可以对人体免疫系统产生一定的抑制作用,有助于多发性硬化症患者体内免疫系统的调节,缓解因免疫系统过度活跃造成的一系列炎症等症状。 美国研究人员在新一期英国《自然-神经学》杂志上报告说,他们通过动物实验首次发现芬戈莫德具有

JAMA Neurol:对复发型多发性硬化芬戈莫德优于传统的注射免疫调节剂

正在接受注射用疾病调节剂治疗的的多发性硬化患者复发后,众多医生都会倾向于转换药物。怎么转换?不同转换药物疗法的疗效如何常常不甚明确。芬戈莫德是一个有效的药物,但是从其他治疗方案里换药到芬戈莫德效果又如何呢?为比较MS复发或者疾病进展后转换药物使用口服免疫调节药芬戈莫德和仍使用注射用免疫调节剂(干扰素或者醋酸格拉默)治疗后两种治疗方案下的复发率,残疾情况,治疗耐受性情况,研究者开展此实验。研究者将来

Baidu
map
Baidu
map
Baidu
map